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Abstract
The combination of hypertension, obesity and non-alcoholic fatty liver disease occurs in medical practice very often. 
A number of studies have shown that non-alcoholic fatty liver disease increases the risk of cardiovascular disease 
independently of other predictors and manifestations of the metabolic syndrome. Current issues of research and 
identification of common pathogenic relationships of obesity, hypertension, and liver steatosis are investigated in 
the article. According to the analysed literature, it is indicated that insulin resistance and compensatory hyperinsu-
linaemia are considered as one of the key factors in the development of this comorbidity. The processes of chronic 
inflammation are increasing with the growth of adipose tissue volume. Some researchers believe that non-specific sys-
temic inflammation combines arterial hypertension, increased body weight (especially abdominal obesity), steatosis, 
dyslipidaemia, atherogenesis and arteriosclerosis into a single syndrome. The role of non-alcoholic fatty liver disease 
in the growth of the thickness of the intima-media complex was studied. It is known that adipose tissue functions 
as an endocrine organ, expresses genes encoding bioactive substances, and secretes certain cytokines. A strong link 
between dysfunction of adipose tissue in patients with non-alcoholic fatty liver disease and in such conditions as 
metabolic syndrome and cardiovascular disease was demonstrated. The dysfunction of the endothelium is also advis-
able to consider as the connecting link between liver disease, obesity and hypertension. Despite some understanding 
of common pathogenic mechanisms for the development of non-alcoholic fatty liver disease and hypertension, this 
comorbid pathology remains the subject of much debate and a variety of studies. 
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Introduction
The prevalence of overweight (OW) and obesity has 
been growing very rapidly worldwide, reaching the 
indicators of the epidemic. The number of patients 
with overweight has already exceeded 2.3 billion of 
the world population. 3 thousands persons with in-
creased body weight are recorded every day [1]. Being 
one of the major modified risk factors (RFs) for the 
development of the cardiovascular (CV) system pa-
thology, obesity leads to its rapid progression, more 
severe course and high frequency of complications. It 
is known that central (abdominal) type of obesity with 
the redistribution of adipose tissue in the abdominal 
region (compared to the lower (femoral-gluteal)) is 
more important RF for the development of CV dis-
eases than the growth of the body mass index (BMI) 
[2–5]. The combination of hypertensive disease (HD) 
and obesity has a poor prognosis [2, 6–8]. 
According to the results of Framingham study, the 
chance of arterial hypertension (AH) development 
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in obesity is 50% higher. Systolic blood pressure 
(SBP) increases in 4.4 mm Hg for every 4.5 kg of 
body weight in men and 4.2 mm Hg in women. 
The positive effects of weight loss on blood pressure 
(BP) have been demonstrated in several large mul-
ticentre studies, such as TOR-1, TAIM, TOMHS, 
XENDOS [9–13].
The urgency of the problem of obesity is also as-
sociated with the fact that it plays an important role 
not only in the development and progression of CV 
diseases, but also in the appearance of non-alcoholic 
fatty liver disease (NAFLD) [1]. A direct correlation 
between body mass index (BMI), hepatic steatosis 
and non-alcoholic steatohepatitis (NASH) is found 
(correlation coefficients are 0.35 and 0.14, respec-
tively, p < 0.001) [7]. According to our data, the 
frequency of detection of hepatic steatosis increased 
progressively with the increasing body mass in 170 
patients with essential hypertension (EH) stage II. 
Hepatic steatosis was identified in 40.0% of hyper-
tensive patients with optimal body weight, 54.1% 
of patients with excess of body weight, 65.5% of pa-
tients with class I obesity and 86.7% of patients with 
class II obesity. The average BMI was significantly 
different between the groups of patients without 
hepatic steatosis and non-alcoholic fatty liver disease, 
29 (24; 32) kg/m2 and 32 (29; 37) kg/m2, respective-
ly; p = 0.0001. It should be noted that abdominal 
type of fat distribution prevailed in patients with 
hypertension and obesity. It was observed in more 
than 80% of patients. The ratio of waist circumfer-
ence to hip circumference (WC/HC) was 0.97 (0.92; 
1.01) in patients with hypertension and obesity in 
the group without steatosis and 0.99 (0.95; 1.03) in 
the group with hepatic steatosis, p = 0.11 for both 
groups. It should be noted that the study did not in-
clude patients with class III–IV obesity and impaired 
glucose tolerance (IGT) or diabetes mellitus (DM). 
The obtained data coincided with the results of other 
researchers, who studied the problems of obesity and 
NAFLD [1, 5, 7, 14–16].
NAFLD combines a wide range of pathologi-
cal conditions from the steatohepatosis to NASH, 
which can progress to cirrhosis and associated 
life-threatening complications [17, 18]. In medical 
practice doctors are often faced with a combination 
of hypertension, obesity and liver diseases [19–24]. 
The comorbidity of hypertension and liver damage 
is the most common in metabolic syndrome (MS). 
Its key factors are insulin resistance and compen-
satory hyperinsulinaemia. They are recognized as 
the leading mechanisms in the pathogenesis of 
NAFLD.
In recent years, NAFLD has been increasingly 
considered as an additional independent risk factor 
of CV diseases and predictor of its complications 
[25–33]. A recent study of life expectancy among 
patients with NAFLD after 24 years of observation 
found that CV diseases were the most common cause 
of death in 48% of patients, while diseases associated 
with liver damage had a lethal outcome in 7% of 
patients [31]. Significantly higher levels of total cho-
lesterol (TC), low-density-lipoprotein (LDL) cho-
lesterol and very-low-density lipoprotein (VLDL) 
cholesterol, triglycerides (TG), atherogenic index, 
serum fasting glucose levels, systolic blood pressure 
(SBP), diastolic blood pressure (DBP), pulse arteri-
al pressure (PAP) and latent myocardial ischaemia 
in electrocardiogram (ECG) among patients with 
NAFLD were recorded [5, 6, 18, 34–37]. Taking 
into account the lack of a clear clinical picture in the 
early stages of its development, NAFLD diagnosis is 
often carried out during the aimed examination of 
patients with obesity and hypertension (EH), their 
combination or other diseases [37, 38]. So, it is diffi-
cult to estimate its real prevalence in the population 
[37, 39–45]. To date, the gold standard of NAFLD 
diagnosis remains the tissue biopsy and biopsy scales, 
the most common of which is semi-quantitative NA-
FLD rating scale (NAS) [43].
Obesity and non-alcoholic fatty liver 
disease
The presence of obesity is important in the mecha-
nisms of NAFLD formation [46]. This relationship 
is explained by the ability of adipose tissue to lead 
to the development of insulin resistance (IR), as the 
process of chronic inflammation increases with the 
increase in adipose tissue volume. The ability of in-
sulin to inhibit the lipolysis is suppressed. This leads 
to the accumulation of non-esterified fatty acids’ 
pool and deposition of triglycerides (TG) in the liver 
structure. Excessive accumulation of TG in the struc-
ture of hepatocytes gradually decreases the ability of 
insulin to suppress hepatic gluconeogenesis and TG 
synthesis, causing the development of hyperglycae-
mia, hyperinsulinaemia and dyslipidaemia [46, 47]. 
When the ability of hepatocytes to accumulate TG 
is exhausted, the damage to the liver cells will occur. 
Inflammatory and apoptotic pathways are activated 
in non-alcoholic hepatic steatosis (NAHS) and stress 
of endoplasmic reticulum in hepatocytes [48]. How-
ever, the role of insulin transfer in the mechanisms 
of liver fatty infiltration development has not been 
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studied. It was noted that the accumulation of fat 
in the liver could also be an independent factor of 
dyslipidaemia [44].
There may be patients who don’t have excessive 
body weight and don’t meet the minimum criteria of 
metabolic syndrome (MS) among the subjects with 
steatohepatosis and non-alcoholic steatohepatitis who 
are not suffering from diabetes mellitus (DM), but 
are in a state of insulin resistance. The received data 
indicate the NAFLD development among individu-
als with IR without signs of type 2 diabetes mellitus 
(DM) and with optimal body weight (OBW) [49].
Insulin resistance and non-alcoholic 
fatty liver disease
The research data indicate that obesity, increased 
serum glucose, insulin, HOMA index as well as 
the laboratory markers of increase in serum C-re-
active protein (CRP) concentration and TG were 
significantly higher in the group with NAFLD in 
comparison with the control group. Triglycerides, in 
turn, support gluconeogenesis and lipid disorders in 
persons with NAFLD as intermediate products of 
metabolism of fatty acids [16]. 
The connection between the “fatty” liver, IR, 
atherosclerosis and metabolic syndrome (MS) was 
demonstrated [43, 50, 51]. The presence of NA-
FLD was associated with the elevated indicators of 
body mass index (BMI), waist circumference (WC), 
low-density-lipoprotein (LDL) cholesterol, lipopro-
tein (LP) and IR [52]. It is suggested that proath-
erogenic serum lipid profile (low high-density-lipo-
protein (HDL) cholesterol; high levels of TG, small 
dense particles of VLDL and apolipoprotein B100), 
which is usually observed in patients with steato-
hepatosis, is responsible for this linkage [14]. The 
transformation of the lipid profile of blood serum 
with the development of type II B dyslipidaemia 
according to Fredrickson classification occurs in IR 
[53]. Enhanced synthesis of TG in the liver and ex-
cessive production of small dense particles of VLDL, 
which reduce the level of high-density-lipoprotein 
(HDL) cholesterol and contribute to the increase 
in the number of low density lipoproteins (LDL) 
particles, are considered the aetiological factors of 
this type of dyslipidaemia [14, 46]. The reducing of 
activity of lipase is also possible. This transformation 
occurs under conditions of insulin resistance, which 
triggers the development of dyslipidaemia [44]. 
There is a hypothesis in the literature that NAFLD 
may develop in the absence of insulin resistance and 
increased activity of lipolysis in adipose tissue. Hepa-
tokines may be involved in cross processes between 
liver and adipose tissue [30].
Non-alcoholic fatty liver disease and 
hypertension
Recently, there have been reports about correlation 
between EH and NAFLD [22, 27, 48]. More than 
50% of NAFLD cases were found in patients with 
hypertension in the absence of other risk factors for 
liver disease. The frequency of NAFLD in patients 
with isolated hypertension (without concomitant 
obesity and diabetes mellitus (DM)) is three times 
higher than in healthy persons of similar age and 
sex [22]. According to the results of some studies of 
systolic hypertension, NAFLD is an independent 
predictor which provokes and worsens the develop-
ment of non-alcoholic steatohepatitis (NASH) [22, 
27]. The greatest number of NASH cases (80%) was 
diagnosed in the group of non-dippers — persons 
with a lack of nocturnal decrease in blood pressure, 
which was associated with high insulin levels [54]. 
These data were confirmed by the results of studies, 
in which BP levels in patients with NAFLD and hy-
pertension at night exceeded the daytime ones. Those 
patients had predominantly the circadian profile of 
non-dippers AP [21, 22]. Similar data were obtained 
in the study of Latea et al. (2013): pathological 
profiles in blood pressure [non-dippers, night-pik-
ers (with nocturnal increase in BP)] dominated in 
patients with NAFLD and over-dippers (excessive 
nocturnal decline of BP). The frequency of having 
NAFLD in groups of non-dippers, night-pikers and 
over-dippers was higher than that in the group of 
dippers (patients with normal noctural decrease in 
BP). The severity of NASH (from moderate to se-
vere) was higher in the group with nocturnal increase 
in blood pressure (night-pikers) [55].
In studies of reverse causality, the prevalence of 
hypertension was 37.6% in patients with NAFLD 
and increased to 46.7% in patients with NASH [56]. 
It has been suggested that the existence and develop-
ment of NAFLD could change the prognosis in hyper-
tensive patients in terms of progression of liver failure 
and increase the incidence of CV complications [48]. 
It was shown that the average intensity of liver steatosis 
was S2 (0.42 to 0.49) among patients with obesity and 
EH stage II. NASH with mild and moderate activity 
was associated with the development of liver tissue 
fibrosis (within F1 — 0.28–0.36) [57]. 
It was found that hypertension, particularly sys-
tolic, was an independent predictor of non-specific 
portal fibrosis in patients with NAFLD [22]. It was 
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obvious that angiotensin II had the leading role in 
the formation of fibrogenesis processes. It was sug-
gested that possible implementation mechanism of 
such effect was the increase in profibrogenic cyto-
kine production, that transformed the growth factor 
(transforming growth factor) — TGF-b1, which ac-
tivated stellate cells. Angiotensin II has not only va-
soconstrictor, but also prothrombogenic action. Also 
it is able to induce the oxidative stress. The experi-
ment confirmed the increase in active oxygen species 
formation (superoxide anion) under the influence of 
angiotensin II. The oxidative stress products reduce 
the activity of nitric oxide (NO). Sometimes angio-
tensin II has the opposite effect in relation to NO 
and now it is recognized as its antagonist. According 
to this fact, the need for pathogenetic therapy of 
hypertension patients with comorbid NAFLD by 
angiotensin-converting enzyme (ACE) inhibitors is 
emphasized. They block the effects of angiotensin 
and aldosterone [22, 58]. The results of recent stud-
ies confirmed the positive effect of ACE inhibitors 
on the state of liver parenchyma. It was shown that 
lower degrees of fibrosis at histological examination 
of the liver and lower levels of transaminases in the 
blood plasma were found in patients receiving ACE. 
Those differences might be associated with the influ-
ence of ACE inhibitors on the renin-angiotensin-al-
dosterone system (RAAS) and effects of angiotensin 
II. It was local RAAS that took part in the regulation 
of liver fibrogenesis and in the genesis of portal hy-
pertension formation [22, 58].
Some authors believe in the unity of pathogenetic 
mechanisms of hypertension development and NA-
FLD [22]. There is an opinion that IR and compen-
satory hyperinsulinaemia are important factors in 
the common pathogenetic mechanisms of NAFLD 
and hypertension development [54, 59–62]. It is 
shown that IR and compensatory hyperinsulinaemia 
are the key factors in the formation of MS [54, 61, 
63]. They are also recognized as the leading mecha-
nisms in the pathogenesis of NAFLD [59, 60, 62]. 
Hyperinsulinaemia, in turn, stimulates the synthesis 
of growth factors (platelet, insulin-like, fibroblast 
growth factor). That leads to the proliferation of 
smooth muscle cells and fibroblasts and, as a conse-
quence, vasoconstriction and increase in blood pres-
sure (BP) [22, 54, 61, 64]. In such conditions, the 
synthesis of endothelin (ET), an inhibitor of tissue 
activator of drug-1, increases [65]. Sympathoadrenal 
system (SAS) and RAAS are involved in the process. 
Sodium reabsorption increases in the proximal and 
distal tubules of nephron, which creates the back-
ground for EH development [22].
So, it is known that NAFLD and hypertension 
are associated with IR and MS. However, there are 
still unresolved issues: What is the causal relationship 
between the development of NAFLD and hyperten-
sion? In what way do the comorbid EH and NAFLD 
affect the development and course of each other? Are 
they parts of a single pathological process? Do they 
have common pathogenetic factors and mechanisms?
Dyslipidaemia and non-alcoholic fatty 
liver disease
Dyslipidaemia, as an important cardiovascular risk 
factor, exerts its influence not only on the vascular 
wall, but also on the physiological processes in the 
structure of liver. In the study by Andres-Blasco et 
al. (2015) it is indicated that NAFLD is associated 
not only with the components of MS such as obesity, 
insulin resistance and hypertension, but also with 
dyslipidaemia [30].
In the body there is a complex system of lipid 
metabolism regulation, in which each link in the 
reticuloendothelial system of liver plays an important 
role [37, 66]. The main components of hepatocellu-
lar lipids are represented by TG [67]. However, today 
the definitive role of triglycerides in assessing of car-
diovascular risk has not yet been proven. Although, 
there was a highly significant direct correlations be-
tween the level of TG and smoking and the levels of 
total cholesterol, hylomicrones, and lipoprotein(a) 
(LP(a)) [39]. Graham et al. indicated that the level of 
TG in blood serum is a “signal” marker for intensive 
examination and determination of such RFs as ab-
dominal obesity, hypertension, high LDL cholesterol 
levels and impaired glucose tolerance [68].
Lipid metabolism in the liver and its changes are 
involved in the development of many pathological 
processes, such as NAFLD, diabetes mellitus (DM) 
and atherosclerosis. The development of dyslipidae-
mia, including hypercholesterolaemia, hypertriglyce-
ridaemia, and the increase in non-esterified fatty ac-
ids associated with the decrease in liver lipase activity 
were noted during the application of a high-calorie 
diet saturated with cholesterol (CS). This, in turn, 
was associated with impaired glucose tolerance, the 
development of an inflammatory process in liver and 
pancreas, and the development of steatosis [30]. 
The increased levels of LDL cholesterol and de-
crease in HDL cholesterol, increased activity of 
CRP, LP(a), and serum neopterin level were noted 
in a study that examined the subclinical markers of 
atherosclerosis in young men with abdominal obesi-
arterial hypertension 2016, vol. 20, no. 4
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ty. This was associated with the presence of obesity 
and steatohepatosis [significant correlation was not-
ed between the thickness of intima-media complex 
(TIMC) and BMI, WC, WC/WH ratio, TG level, 
neopterin, CRP, alanine aminotransferase (ALAT), 
aspartate aminotransferase (ASAT), and gamma-glu-
tamyltransferase (GGT)] [25]. According to the ob-
tained data, the authors proposed the use of the 
markers of inflammation, increased levels of ALAT, 
ASAT, GGT and the presence of NAFLD as the pre-
dictors of subclinical atherosclerosis [25].
Lipid metabolism in the liver is regulated by pro-
tein-receptor of low density lipoprotein-6 (LRP6). 
Apolipoproteins recognition by receptors in neu-
tral pH leads to the internationalization of the li-
gands, followed by distribution to endosome. The 
released particles of the ligands are transported to 
lysosome, where the digestive enzymes break down 
these ligands. The pathological pathway of IGF-
1-Sp1-mTOR-SREBP1/2 is activated during the 
impairment of signalling protein-receptor LRP6 
function. Activation of Sterol Regulatory Element 
Binding Protein1c (SREBP1c), involved in lipo- and 
adipogenesis, and SREBP2 (which activates choles-
terol biosynthesis and LDL receptors) support adi-
pogenesis and accumulation of VLDL cholesterol, 
which take part in the development of hyperlipi-
daemia and NAFLD. The state of lipid metabolism 
in hepatocytes depends on such pathological way of 
consumption as mTOR, which is supported by the 
serine/threonine kinase. Protein kinase B, activated 
by insulin, phosphorylates and suppresses tuberous 
sclerosis complex 2 (TSC2) a tumour suppressor. 
This leads to the activation of mTORC1 peptide 
S6, S6K and SREBP. TSC1-TSC2 complex disorder 
promotes SREBP-dependent lipid synthesis similarly 
[69, 70]. Activation of mTORC1 signalling pathway 
is associated with an increase in lipid synthesis and 
the development of non-alcoholic steatohepatosis. 
In addition, stimulation of the mTOR pathological 
pathway contributes to the insulin-dependent tran-
scription of stearoyl-CoA desaturase (SCD1), an im-
portant enzyme that regulates the synthesis of mono-
unsaturated fatty acids and lipogenesis in the struc-
ture of hepatocytes and lipid oxidation. It is proved 
in experimental work that SCD1, associated with the 
work of the hepatocytes, protects experimental mice 
from carbohydrates-induced deposition of adipose 
tissue and development of steatohepatosis [71].
Prognostic value of a significant increase in LP(a) 
in serum, as an important predictor of CV events, 
was confirmed in the studies that included patients 
with dyslipidaemia, hypertension, diabetes, the his-
tory of CV disease and non-alcoholic hepatic steato-
sis (NAHS) [38, 72, 73]. In parallel, the role of LP(a) 
as a genetic risk factor for CV disease was explained. 
Its value may be associated with the level of LDL 
cholesterol [68]. The role of hypertriglyceridaemia 
and increased VLDL cholesterol has been confirmed 
in the pathogenetic mechanisms of NAFLD forma-
tion [30, 46, 74]. LP(a) role in the development of 
NAFLD remained completely undetermined. The 
obtained data are rather contradictory. Lee et al. 
(2006) showed the decrease in LP(a) in patients with 
NAFLD. Also, Cankurtaran et al. (2007) record-
ed the increase in LP(a) in patients with NAFLD. 
Moreover, the study of lipid and carbohydrate me-
tabolism in patients with NAFLD found that the in-
crease in LDL cholesterol was accompanied by LP(a) 
concentration, CRP in serum, impaired tolerance to 
carbohydrates and increased levels of fasting insulin 
[50]. The correlation between LP(a) and IR were 
examined in the study in which the concentration 
of LP(a) was decreased more effectively in patients 
without IR syndrome [75].
Today, the activation of lipid peroxidation (LPO) 
processes in the background of an active lipogenesis 
in the pathogenesis of NAFLD is seen as a factor of 
accelerated atherosclerotic process [76]. So, foamy 
macrophages are formed during the modification 
of LDL by malonic dialdehyde (MDA) as a result 
of hydrolysis and esters’ esterification in LDL. This 
contributes to the development of proinflammatory 
and proatherogenic reactions [77]. In the pathogen-
esis of NAFLD, protein-modifying effects, mediated 
by MDA and hydroxynonenal (HNE), manifested 
by the formation of protein adducts, in particular 
Lys-residues apo B100. This promotes the formation 
of atherosclerotic plaques.
Nonspecific systemic inflammation
Macrophages, accumulating in adipose tissue, are 
a source of local cytokine that is involved in the 
development of NAFLD — tumour necrotic fac-
tor a (TNF-a). Particularly intensive synthesis of 
TNF-a is characteristic of the visceral fat depot, 
which produces 2–3 times more TNF-a compared 
with subcutaneous adipose tissue. Infiltration of vis-
ceral adipose tissue by macrophages is observed in 
conditions of pronounced hypertrophy in combi-
nation with increased secretion of proinflammatory 
cytokines, in particular TNF-a. TNF-a, in turn, 
is a potent inducer of the formation of interleu-
kin-1 (IL-1), interleukin-6 (IL-6), C-reactive protein 
(CRP) and other compounds with the subsequent 
development of insulin resistance and a cascade of 
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related metabolic disorders [65, 76, 78]. Adipocytes 
of the omentum and mesenteric area are character-
ized by high lipolytic ability, resulting in a massive 
flow of free fatty acids (FFA) and adipokines in the 
liver with the subsequent development of insulin 
resistance and dyslipidaemia. The molecules of re-
active oxygen potentiate the oxidation of fatty acids 
in combination with the damage of hepatocytes and 
the production of proinflammatory cytokines. This 
stimulates the development of nonspecific systemic 
inflammation. Proinflammatory cytokines (TNF-a 
and IL-6) activate lipogenesis and inhibit oxidation 
of free fatty acids (FFA) in liver cells, resulting in in-
creased apolipoprotein B (apoB) and VLDL. TNF-a 
and IL-6 inhibit the catabolism of chylomicrons 
and VLDL, leading to the development of signifi-
cant hypertriglyceridaemia — the trigger factor of 
NAFLD development [79, 80]. Patients with fatty 
liver disease have increased levels of matrix RNA 
(mRNA) of TNF-a and receptors to this cytokine. 
TNF-a damages the metabolism of apoproteins due 
to the suppressive effect on the secretion of apoE and 
apoA1 proteins. It is necessary to mention that insu-
lin resistance and local liver inflammation activate 
the macrophages of liver (Kupffer cells) that begin 
to synthesize proinflammatory cytokines (TNF-a, 
IL-12 and IFN-g) [18]. Consequently, the metabolic 
disorder in the liver is the background for the de-
velopment of chronic inflammatory process of low 
severity [33]. It is shown that it is non-specific sys-
temic inflammation that brings together into a uni-
tary syndrome hypertension, increased body weight 
(especially abdominal obesity), dyslipidaemia and 
atherogenesis [81]. Significant (p < 0.001) increase 
in inflammation markers (TNF-a, IL-1, IL-6) and 
increase (p < 0.001) in the circulating immune com-
plexes’ level were identified in patients with comor-
bidity (a combination of hypertension, obesity and 
NAFLD [75].
Adipose tissue and its activity
According to the approach of modern medicine, adi-
pose tissue functions as an endocrine organ, expresses 
genes encoding bioactive substances, secretes certain 
cytokines, which are called “adipocytokines” [82]. 
This specifies its considerable activity in relation to 
metabolic processes: the larger it becomes, the more 
it produces hormones and biologically active sub-
stances (leptin, resistin, adiponectin, apelin, proin-
flammatory cytokines, growth factors, complement 
factors and others), that participate in inflammation 
processes, including atherosclerosis [8, 18, 83, 84]. 
An excessive amount of these molecules is associated 
with the alteration in insulin sensitivity. A strong link 
between dysfunction of adipose tissue in patients 
with NAFLD and such conditions as metabolic syn-
drome, type 2 diabetes and CV disease was demon-
strated [15].
Leptin is involved in the regulation of body weight 
and plays a significant role in the accumulation of 
TG in the liver. Increase in its content is associated 
with the elevation of ALT levels and may be in-
volved in the promotion of hepatocellular damage. 
The amount of leptin secreted is in direct proportion 
to the mass of adipose tissue [85]. Recently, leptin is 
considered as a mediator of activation of the sympa-
thetic nervous system (SNS), which plays a role in 
so-called leptin-induced increase in blood pressure 
[86]. In obesity, leptin concentration is increased 
and expression of leptin receptors is reduced, which 
is characterized as “leptin resistance” and can be 
manifested both systemically and at the level of the 
liver [22].
The levels of resistin (another adipocytokine) in 
NAFLD are also elevated and associated with the 
histological severity of the disease. It is shown that 
the reduction of body weight significantly reduces its 
level [18, 87]. The results of the study indicate that 
resistin can serve as a metabolic bridge that connects 
inflammation and atherosclerosis [88]. It is reported 
that in individuals with and without diabetes the 
level of resistin in plasma is associated with metabol-
ic and inflammatory markers, that include soluble 
receptors of TNF, IL-6 and lipoprotein-associated 
phospholipase. The concentration of resistin is also 
associated with the severity of coronary arteries’ calci-
fication, and is the independent predictor and mark-
er of atherosclerosis [89]. The relationship between 
the level of resistin and the markers of endothelial 
dysfunction confirms the potential effects of resistin 
in the development of CV disease. The association 
between obesity, inflammation and resistin expres-
sion is complex, and a final clarification of its role 
requires further research.
Adiponectin is collagen-like protein specific to 
adipose tissue, which owns antiatherogenic, anti-in-
flammatory and antidiabetic properties. It is adi-
pocytokine, involved in the inhibition of NAFLD 
[24, 54, 75, 90–92]. Adiponectin is influenced by and 
affects the action of many pathophysiological mecha-
nisms, including nonspecific systemic inflammation, 
increase/decrease in body weight, body constitution 
and chronic diseases [77]. Lower concentration of ad-
iponectin in serum is noted in patients with NAFLD 
[90, 93]. There is evidence that its concentration is 
negatively correlated with the content of fat in the 
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liver. Adiponectin stimulates b-oxidation through 
activation of AMP-dependent protein kinase and re-
duces the key transcription factor of de novo synthesis 
of fatty acid. This leads to the reduced accumulation 
of TG in the liver. Adiponectin has antioxidant prop-
erties as an antagonist of the inflammatory media-
tors’ effect of TNF-type and reduces the proliferation 
of stellate cells of the liver [91]. In several studies, the 
decrease in adiponectin levels is an early predictor 
of the development of MS and CV disease and is 
considered as an additional factor of high mortality 
rate [77]. Expression of adiponectin is impaired in 
patients with obesity. This may contribute to the 
progression of changes in liver tissue (non-alcoholic 
steatohepatosis (NASH) — steatohepatitis (SH) — 
fibrosis) or start the cascade of metabolic events with 
the formation of dyslipidaemia and hypertension 
[22]. On the other hand, some authors indicate that 
the elevated levels of insulin and adiponectin were 
recorded in patients with NAFLD [54]. It is evident 
that high adiponectin level is associated with the con-
gestive heart failure and mortality [94, 95].
So, the final clarification of adiponectin and an-
other adipokines role in the development of NAFLD 
and other diseases requires further researches. It is 
suggested that based on the adipokine levels it will be 
possible to predict not only the development of ste-
atosis and the severity of NAFLD, but also AH [22].
Endothelial dysfunction 
The dysfunction of endothelium may be considered 
as the link between the pathology of liver, obesity 
and hypertension [96]. The vasoregulatory role of 
the local fat depot around the vascular wall should 
be noted [97]. The vascular endothelium is an ac-
tive, dynamic structure that receives the mechanical 
and hormonal stimuli and selects the agents which 
regulate vasomotor function, trigger inflammatory 
processes and affect haemostasis. Excess body weight 
and the development of abdominal obesity not only 
increase the frequency of other cardiovascular risk 
factors, including dyslipidaemia, hypertension, in-
sulin resistance, and hyperglycaemia, but also lead 
to the increased activity of renin-angiotensin sys-
tem, synthesis of adipocytokines, activation of the 
processes of nonspecific systemic inflammation, in 
particular increasing of TNF-a concentration level 
in the serum, which has a negative impact on the 
vascular endothelium [98].
Chronic nonspecific systemic inflammation re-
sults in a decrease in nitric oxide (NO) production 
by vascular endothelial cells and reduced ESVD, 
contributing to the invasion of LDL cholesterol in 
endotheliocytes and its oxidation in the vascular wall, 
followed by capture by macrophages with the forma-
tion of foam cells [96]. These reactions can reduce 
the elastic properties of the arteries and cause the 
development of endothelial dysfunction (ED). Dif-
ferent studies of the concentrations of inflammation 
markers such as high sensitive CRP, TNF-a, IL-6, 
leukocytes count in patients with NAFLD were con-
ducted [84, 93, 99]. It was shown that nonspecific 
chronic systemic inflammation had led to the devel-
opment of ED in patients with NAFLD [93, 96, 99]. 
Zitona link of immunity is considered as one of the 
pathogenetic factors in the formation of ED, the pro-
cesses of cytolysis in hepatocytes and the subsequent 
development and progression of NAFLD.
The endothelium of the liver sinusoids is a highly 
specialized structure and phenotypically highly dif-
ferentiated due to the presence of fenestration and 
lack of a basal membrane, which distinguishes them 
from other endothelial cells. Sinusoidal endothelium 
of the liver accounts for about 3% of the liver struc-
ture and is responsible for the clearance of liver se-
rum molecules that pass through the sinusoid [100]. 
The impression of endothelial cells occurs in various 
liver diseases, including NAFLD. However, the rela-
tionship between the lesions of endothelial cells and 
NAFLD development is completely undetermined. 
The question about the value of the sinusoidal ED 
for the development of fibrosis in NAFLD remains 
open. The value of high-calorie diets for the devel-
opment of sinusoidal ED was demonstrated in the 
experiment on rat metabolic syndrome model. It was 
shown that ED hepatic sinusoids occurred before the 
development of inflammation or fibrosis [101]. Ac-
cording to the results of other experimental studies, 
it was established that the impression of sinusoidal 
endothelial cells developed in the presence of the 
non-alcoholic steatohepatosis and preceded the acti-
vation of Kupffer cells and stellate cells of the liver. 
The obtained results indicated that the impression of 
sinusoidal endothelial cells was the ”warning signal” 
of progression of simple steatosis to non-alcoholic 
steatohepatitis and was a prerequisite for the acti-
vation of Kupffer cells and stellate cells of the liver. 
This determined the development and formation of 
chronic liver injury [102].
The NAFLD value for the functional state of 
the vascular endothelium was established in the 
review of 11 studies. It was shown that the pres-
ence of NAFLD was associated with the reduced 
endothelium-dependent vasodilation (REDV), 
mainly in patients with obesity [103]. Long et al. 
(2015) found that fatty infiltration of the liver was 
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associated with REDV, the increase in the pulse 
wave propagation velocity (PWPV) and higher AP 
(samples included 2284 patients with fatty hepa-
tosis without marked CV disease) according to the 
multiple correlation analysis with indices of age, 
sex, smoking, DM, hyperlipidaemia, blood pres-
sure, and BMI [104]. It was also shown that the 
reduction of brachial artery REDV correlated with 
the degree of morphological changes in the liver, 
regardless of sex, age, insulin resistance and other 
MS components [105, 106]. The relationship of 
ED with steatohepatosis was also recorded in the 
study of Katsiki et al. (2015) that was conducted 
in patients with MS and NAFLD [107].
Thickness of intima-media complex
Attempts to explore the relationship between the 
thickness of intima-media complex (TIMC) and ear-
ly manifestations of atherosclerosis in patients with 
NAFLD are being made. The role of NAFLD in the 
growth of TIMC is also being studied. It is estab-
lished that TIMC is greater in patients with NAFLD 
in comparison with the control group, independent-
ly of other traditional RF and the presence of MS 
[26, 28, 93, 108]. In patients with NAFLD the TIMC 
value is 1.14 mm on average. It increases the risk of 
CV diseases. NAFLD can act as a trigger factor of the 
TIMC increase, and the increase in TIMC depends 
on the NAFLD severity [108, 109]. A meta-analysis 
of 8 observational studies indicated a reliable associ-
ation between TIMC and CV risk. It was repeatedly 
noted that TIMC increase and the presence of ath-
erosclerotic plaques of the carotid arteries might be 
a predictor of myocardial infarction (MI) and stroke. 
The ratio of TIMC and CV risk is continuum, but 
the criterion for a significant risk increase may be the 
threshold of TIMC equalled to 0.9 mm and more 
[110–112]. The value of fat steatohepatosis as an 
additional CV risk factor was confirmed by studies of 
Marcucci et al. (2010). It was noted that the presence 
of NAFLD along with the SBP, BMI, and WC was 
significantly associated with TIMC [26]. The results 
of the study were unexpected. It was indicated that 
there was no association between TIMC and well-
known cardiovascular risk factors such as dyslipi-
daemia, increased fasting glucose levels and insulin 
resistance. Thus, not all cardiovascular risk factors are 
able to exercise the same influence on TIMC. Some 
of them are important for the later development of 
atherosclerosis, for example, the formation of athero-
sclerotic plaque.
Arterial stiffness
In recent years, increasing attention of researchers is 
focused on the arterial wall stiffness (AWS), which 
characterizes the structural changes of the vessels 
[113, 114]. The results of recent studies indicate that 
the old theory of AWS development (as a result of 
atherosclerotic changes of the vascular wall) is in-
correct. Arterial stiffness develops due to arterioscle-
rosis, which is different from atherosclerosis and is 
indicated by the absence of associative relationships 
between the propagation velocity of the pulse wave 
(PVPW) and traditional cardiovascular risk factors, 
with the exception of age and hypertension. In addi-
tion, PVPW does not increase in the early stages of 
atherosclerosis and increases with the development 
of atherosclerotic plaques, mainly due to calcifica-
tion of the arterial wall [31]. The increase in AWS in 
NAFLD was found [115–117]. However, the patho-
genetic mechanisms of AWS formation in patients 
with NAFLD are completely unclear. One of the 
hypotheses points to the development of nonspecific 
systemic inflammation in patients with NAFLD, 
when CRP and pro-inflammatory cytokines may ex-
ercise a negative impact on the arterial wall elasticity 
of the arteries with large diameter. The elasticity of 
the arteries was lower in patients with NAFLD. No 
changes in the elasticity of the vascular wall were 
observed in patients with NAFLD and a low level 
of CRP. Abdominal obesity, in turn, is an unfavour-
able determinant not only for AWS, but also for 
the rising levels of CRP in patients with NAFLD 
[31, 115, 118–120]. Young men and middle aged 
persons without concomitant obesity, hypertension 
and diabetes were selected to explore the association 
between NAFLD and AWS, and to exclude the influ-
ence of age, obesity, hypertension, diabetes and other 
factors. The authors noted a significant increase in 
leukocyte count in patients with NAFLD compared 
with the control group. This indicates the possible 
involvement of inflammation in the pathogenesis of 
NAFLD. A significant increase in CRP index, which 
is independently associated with PVPW and AWS 
increase, confirmed the hypothesis [117]. Another 
point of view on the pathogenetic mechanisms of 
AWS increase is associated with the total blood vis-
cosity. Blood viscosity was higher in patients with 
NAFLD and was independently associated with 
AWS, even after adjusting for other risk factors. NA-
FLD connection with AWS increase was presented in 
the study of Lee et al. (2012). An independent asso-
ciation between PVPW and NAFLD, independently 
of other cardiovascular risk factors, was found with 
the help of multivariate regression analysis [116]. 
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The influence of NAFLD on PVPW also was dis-
covered in the studies of Chung (2015), and Chou 
(2015). Overall, 2954 patients participated in the 
first study. It was found a reliable independent asso-
ciation between NAFLD and cardio-ankle vascular 
index [121]. Another study evaluated the association 
between NAFLD and AWS in healthy persons with 
normal glucose levels, patients with impaired toler-
ance to carbohydrates and newly diagnosed diabetes. 
The effect of NAFLD on AWS among the individ-
uals without signs of metabolic disorders was noted. 
There was no such association among patients with 
impaired tolerance to carbohydrates and newly di-
agnosed DM [115]. It was established that patients 
with histologically confirmed diagnosis of NAFLD, 
assessed according to the Brunt scale (Brunt of the 
Global Grade), had significantly higher PVPW rates 
(8.2 ± 1.3 m/s versus 6.9 ± 1.3 m/s, p = 0.001), great-
er TIMC (0.79 ± 0.18 m/s vs. 0.67 ± 0.13 m/s, p = 
0.01) and lower EDVD (1.93 ± 2.11% versus a 4.8 
± 2.43%, p = 0.001) compared with patients without 
NAFLD [28]. The data were confirmed by the results 
of a systematic review of 36 studies, 16 of which had 
investigated the association between NAFLD and 
TIMC of carotid arteries, 7 — the relationship be-
tween NAFLD and calcification of carotid arteries, 7 
with ED, and the rest 6 with AWS [29].
Steatohepatosis and its metabolic 
consequences
What are the metabolic consequences of the steato-
hepatosis? Accumulation of fat in the liver causes 
hyperglycaemia, subclinical inflammation, dyslipi-
daemia and production of hepatokines, thereby lead-
ing to insulin resistance, atherosclerosis and possible 
dysfunction of b-cells and apoptosis. The severity of 
these conditions can be moderate (benign fatty infil-
tration of the liver). The same degree of steatosis may 
be accompanied by the significant liver lipotoxicity 
and lead to the aggravation of hyperglycaemia, in-
flammation, dyslipidaemia, unbalanced hepatokines 
production and subsequent metabolic disorders due 
to unestablished mechanisms [47]. The NAFLD de-
velopment is closely associated with such MS com-
ponents as insulin resistance, abdominal obesity, 
dyslipidaemia and hypertension. It is based on the 
impairment of mechanisms of insulin-mediated li-
polysis processes inhibition and increased release of 
free fatty acids (FFA) from adipose tissue. A number 
of studies found that NAFLD increased the risk of 
CV diseases independently of other predictors and 
manifestations of MS [34].
Anthropometric characteristics of NAFLD on the 
background of MS were revealed. It was shown that 
the severity of hepatic steatosis was closely associated 
with BMI, WC/HC ratio and body fat percentage. 
The increased degree of steatosis in the presence of 
IR not only deteriorated the functional state of the 
liver, but also increased the severity of dyslipidaemia. 
Statistically significant direct correlations between 
the degree of IR and the level of AST, ALT, TH, TG, 
hepatic steatosis and anthropometric data showed 
that metabolic parameters could be considered as 
factors, the regulation of which affected the develop-
ment and progression of NASH on the background 
of MS [19]. 
A combination of such risk factors as hypergly-
caemia, dyslipidaemia, hypertension, abdominal 
obesity, disorders of the haemostatic system in the 
presence of insulin resistance creates a pathogenetic 
prerequisite for the disorders of CV system function 
in patients with NAFLD. In this aspect, the car-
dio-dynamic changes in NAFLD, the time of their 
development, the nature of the occurrence and the 
association with the state of the portal blood flow are 
very interesting [17]. Diastolic dysfunction due to 
the flow-dependent regulation of vascular tone can 
also act as a marker of subclinical atherosclerosis. The 
present study showed strong correlation between it 
and NAFLD (the greater the liver damage in NA-
FLD (from simple steatohepatosis, inflammation 
with manifestations of necrosis to the development 
of fibrosis), the more severe diastolic dysfunction) 
[22, 105, 122]. Thus, NAFLD can act as an addi-
tional predictor of CV disease.
Conclusions
A review of studies to identify the relationship be-
tween CV and NAFLD diseases indicates that NA-
FLD can be considered as one of the phenotypic 
variants of insulin resistance and MS. The participa-
tion of insulin resistance, oxidative stress, subclinical 
nonspecific inflammation, disorders of lipid metab-
olism and endothelial dysfunction in pathogenetic 
relationships between NAFLD and cardiovascular 
disease can be applied for therapeutic prospects in 
the treatment of these diseases [32]. 
The combination of AH and NAFLD are prereq-
uisites for the progression of the pathological pro-
cess, which has targeted the heart, kidneys and liver 
[8, 66, 103]. Taking into account the fact that NAFLD 
is considered within a continuum of the MS, an 
interesting issue is the study of the nature of changes 
in the CV system in such category of patients [20]. 
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Thus, despite some understanding of common 
pathogenic mechanisms of NAFLD development and 
hypertension, this comorbid pathology is the subject 
of much scientific debate and various studies [6–8, 
14, 20, 22, 27, 31, 32, 48, 54, 55, 57, 58, 61, 96, 
121]. The question of carrying out further observa-
tions for a deeper study of pathogenesis is relevant. 
It is necessary to identify the ways and methods of 
prevention and correction of metabolic disorders, de-
veloping in these states. Today, only an individual 
approach to each patient with deep detailed diagnosis 
of main clinical and metabolic manifestations, as well 
as a comprehensive approach to treatment, taking into 
account coexisting pathologies, will help to prevent 
further progression of these diseases, reduce the risk of 
complications and improve the quality of patients’ life. 
Conflict of interest: none declared.
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